Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page:
About CDC.gov

Fifty-nine participants were enrolled. No changes were seen in glucose level, insulin level, or HOMA-IR (all, P>.05) after 6 months of chromium at either dosage level (500 mcg or 1000 mcg daily) when compared with placebo. None of the secondary outcomes improved with either chromium dosage compared with placebo (P>.05).

Conclusions

Chromium supplementation does not appear to ameliorate insulin resistance or impaired glucose metabolism in patients at risk for type 2 diabetes and thus is unlikely to attenuate diabetes risk.

The total prevalence of diabetes and impaired glucose tolerance in U.S. adults aged 20-74 years was obtained from medical history and oral glucose tolerance tests. Plasma glucose distributions, associations with selected medical, genetic, and clinica...

Task Force on Community Preventive Services (U.S.); Centers for Diseases Control and Prevention (U.S.); Centers for Diseases Control and Prevention (U.S.), Epidemiology Program Office., Division of Prevention Research and Analytic Methods.; National Center for Chronic Disease Prevention and Health Promotion (U.S.), Division of Diabetes Translation.;

Reducing morbidity and mortality and improving quality of life for persons with diabetes is an ongoing challenge for health-care providers and organizations and public health practitioners. Interventions are available that focus on persons with diabe...